OBJECTIVE: To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis. DESIGN: Prospective experimental study. SETTING: Animal research and laboratory facility. ANIMAL(S): Two-month-old female BALB/c mice. INTERVENTION(S): Surgically induced endometriosis in female BALB/C mice; 28 days of treatment with celecoxib, rosiglitazone, or their combination; counting, measuring, excising, and fixing lesions. MAIN OUTCOME MEASURE(S): Immunohistochemical examination for proliferating cell nuclear antigen (PCNA), CD31, and CD34 to assess cell proliferation and vascularization, with the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) technique for apoptosis evaluation. RESULT(S): Celecoxib and the combined treatment (celecoxib and rosiglitazone) statistically significantly reduced the mean number of lesions established per mouse, and all treatments diminished the implant volume. In addition, cell proliferation within the implants was statistically significantly reduced, and apoptosis was statistically significantly enhanced by all treatments. Also, we found that all treatments diminished the vascularized area in the lesion. CONCLUSION(S): These results are promising and reveal that celecoxib and rosiglitazone, combined or separately, have a beneficial effect on overall endometriotic growth.
OBJECTIVE: To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis. DESIGN: Prospective experimental study. SETTING: Animal research and laboratory facility. ANIMAL(S): Two-month-old female BALB/c mice. INTERVENTION(S): Surgically induced endometriosis in female BALB/C mice; 28 days of treatment with celecoxib, rosiglitazone, or their combination; counting, measuring, excising, and fixing lesions. MAIN OUTCOME MEASURE(S): Immunohistochemical examination for proliferating cell nuclear antigen (PCNA), CD31, and CD34 to assess cell proliferation and vascularization, with the terminal deoxynucleotidyl transferasedUTP nick end labeling (TUNEL) technique for apoptosis evaluation. RESULT(S): Celecoxib and the combined treatment (celecoxib and rosiglitazone) statistically significantly reduced the mean number of lesions established per mouse, and all treatments diminished the implant volume. In addition, cell proliferation within the implants was statistically significantly reduced, and apoptosis was statistically significantly enhanced by all treatments. Also, we found that all treatments diminished the vascularized area in the lesion. CONCLUSION(S): These results are promising and reveal that celecoxib and rosiglitazone, combined or separately, have a beneficial effect on overall endometriotic growth.
Authors: Leticia Muñoz-Hernando; Jose L Muñoz-Gonzalez; Laura Marqueta-Marques; Carmen Alvarez-Conejo; Álvaro Tejerizo-García; Gregorio Lopez-Gonzalez; Emilia Villegas-Muñoz; Angel Martin-Jimenez; Jesús S Jiménez-López Journal: Int J Womens Health Date: 2015-06-11
Authors: Allison F Vitonis; Katy Vincent; Nilufer Rahmioglu; Amelie Fassbender; Germaine M Buck Louis; Lone Hummelshoj; Linda C Giudice; Pamela Stratton; G David Adamson; Christian M Becker; Krina T Zondervan; Stacey A Missmer Journal: Fertil Steril Date: 2014-09-22 Impact factor: 7.329
Authors: Carla N Olivares; Laura D Alaniz; Michael D Menger; Rosa I Barañao; Matthias W Laschke; Gabriela F Meresman Journal: PLoS One Date: 2016-03-28 Impact factor: 3.240
Authors: Gabriella Zito; Stefania Luppi; Elena Giolo; Monica Martinelli; Irene Venturin; Giovanni Di Lorenzo; Giuseppe Ricci Journal: Biomed Res Int Date: 2014-08-07 Impact factor: 3.411